STOCK TITAN
  1. Home
  2. News
  3. KTTA

Pasithea Therapeutics Corp. - KTTA STOCK NEWS

Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.

Pasithea Therapeutics Corp. (symbol: KTTA) is a forward-thinking biotechnology company dedicated to the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. By leveraging advancements in the fields of neuroscience, translational medicine, and drug development, Pasithea Therapeutics aims to address unmet medical needs and improve patient outcomes.

The company's robust pipeline includes promising treatments for Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. These conditions represent significant therapeutic challenges, and Pasithea Therapeutics is committed to advancing research to bring effective solutions to market.

Recent achievements highlight the company's progress in translating scientific discoveries into potential therapeutic applications. Notably, initial safety, tolerability, and biomarker data are expected to be reported in the second half of 2024. This milestone will be crucial in validating the efficacy of their treatments and guiding future development.

As a driver of innovation in biotechnology, Pasithea Therapeutics collaborates with leading researchers, healthcare providers, and institutions to enhance its research capabilities and expedite the drug development process. Strategic partnerships play a pivotal role in the company's ability to stay at the forefront of scientific advancements and bring new therapies to patients in need.

The financial condition of Pasithea Therapeutics is underscored by its commitment to transparency and robust corporate governance. The company continuously strives to maintain a solid financial foundation to support its research and development activities.

Stay updated with the latest news and developments from Pasithea Therapeutics by checking their regular press releases and corporate communications. For more information, please contact Patrick Gaynes, Corporate Communications, at pgaynes@pasithea.com.

News

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Rhea-AI Summary
Pasithea Therapeutics Corp. announces the completion of initial dosing for the first cohort in a Phase 1 trial evaluating PAS-004 in RAS, NF1, and RAF mutated cancers. Safety, tolerability, and biomarker data expected in 2H 2024. PAS-004 is a next-generation MEK inhibitor for neurofibromatosis type 1 (NF1) and other indications, showing potential as a best-in-class inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
clinical trial
-
News

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the activation of four U.S. clinical trial sites for Phase 1 trial of PAS-004, a next-generation MEK inhibitor for treating NF1 and other cancer indications. The company plans to open three more sites in Eastern Europe. Preliminary interim data is expected in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.95%
Tags
clinical trial
-
News

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announces the invention of a crystalline form of PAS-004, extending patent protection to at least 2045. The company is focused on developing innovative treatments for CNS disorders, with a strong emphasis on expanding its patent portfolio and increasing the value of PAS-004 through additional CMC development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
none
News

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the FDA clearance to evaluate PAS-004, a macrocyclic MEK inhibitor, in patients with MAPK pathway driven advanced solid tumors. The phase 1 dose escalation study is expected to begin in Q1 2024, with an initial readout anticipated as early as Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.78%
Tags
clinical trial
-
News

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) adjourns stockholder meeting to provide additional time for voting on charter amendment proposals. The reconvened meeting will take place on December 29, 2023, with the original record date remaining the same. Stockholders are encouraged to vote promptly, and proxies previously submitted will be voted at the adjourned meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
none
-
News

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) Holds Annual Meeting and Receives Overwhelming Support for Approved Proposals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.58%
Tags
none
News

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Rhea-AI Summary
Pasithea Therapeutics Corp. (KTTA) announced positive preclinical results for PAS-004, a potential treatment for Central Nervous System disorders. PAS-004 demonstrated superior anti-tumor efficacy in lung and liver cancer models compared to FDA-approved MEK inhibitors. The company plans to start a Phase 1 trial in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.33%
Tags
none
-
News

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) adjourns its annual meeting of stockholders to December 19, 2023, to allow additional time for stockholders to vote on proposals outlined in the Proxy Statement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
none
-
News

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) plans to submit PAS-004 IND application in the current quarter and begin a Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF, and NF1 mutations. The FDA's positive feedback and guidance include a recommendation to begin dosing in patients who will benefit from treatment rather than in healthy volunteers. PAS-004 was granted orphan drug designation for the treatment of NF1 in November 2020. Dr. Tiago Reis Marques, CEO of Pasithea, expressed excitement to begin testing PAS-004 in a first-in-human Phase 1 dose escalation trial in early 2024 following acceptance of the IND by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
clinical trial
News

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the selection of a lead therapeutic candidate for its PAS-003 program, a humanized monoclonal antibody targeting α5β1 integrin, showing promise for the treatment of ALS. The antibody has been optimized for high affinity and specificity, ready for manufacturing and IND-enabling studies. Extensive preclinical studies have validated the candidate's efficacy in both sporadic and familial ALS mouse models, with potential implications for human patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Pasithea Therapeutics (ktta)?

The current stock price of Pasithea Therapeutics (ktta) is $2.525 as of January 14, 2025.

What is the market cap of Pasithea Therapeutics (ktta)?

The market cap of Pasithea Therapeutics (ktta) is approximately 3.0M.

What does Pasithea Therapeutics Corp. specialize in?

Pasithea Therapeutics Corp. specializes in the discovery, research, and development of treatments for central nervous system (CNS) disorders and RASopathies.

What diseases are included in Pasithea Therapeutics' pipeline?

The pipeline includes treatments for Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.

When is the initial safety and biomarker data expected to be reported?

The initial safety, tolerability, and biomarker data are expected to be reported in the second half of 2024.

Who can be contacted for more information about Pasithea Therapeutics?

For more information, you can contact Patrick Gaynes, Corporate Communications, at pgaynes@pasithea.com.

How does Pasithea Therapeutics advance its research?

Pasithea Therapeutics advances its research through collaborations with leading researchers, healthcare providers, and institutions, focusing on innovation in neuroscience and translational medicine.

What is the significance of Pasithea Therapeutics' work?

Pasithea Therapeutics' work is significant in addressing unmet medical needs and improving patient outcomes for complex CNS disorders and other diseases.

Does Pasithea Therapeutics provide regular updates?

Yes, Pasithea Therapeutics provides regular updates through press releases and corporate communications.

What are the core areas of research for Pasithea Therapeutics?

The core areas of research include treatments for CNS disorders, leveraging neuroscience and drug development to address conditions like ALS, MS, and Schizophrenia.

What are RASopathies?

RASopathies are a group of disorders caused by mutations in the RAS gene, affecting cell growth and development, which Pasithea Therapeutics aims to treat through their innovative research.

How does Pasithea Therapeutics support its financial stability?

Pasithea Therapeutics supports its financial stability through transparent corporate governance and maintaining a solid financial foundation to back its research and development activities.
Stock KTTA logo
Pasithea Therapeutics Corp.

Nasdaq:KTTA

KTTA Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

KTTA Stock Data

3.01M
1.02M
23.12%
2.87%
1.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
VENICE